503Pharma Weekly Compounding Pharmacy Roundup

JOIN FREE MEMBERS AREA | COMPLIANCE TRAINING | FORMULA LIBRARY

This Week's Headlines

Market

Lilly's Foundayo Hits U.S. Pharmacies

Lilly's oral GLP-1 pill Foundayo (orforglipron) is now at retail pharmacies and telehealth — $149/month self-pay, no food or water restrictions, any time of day. Approved in 50 days under FDA's fast-track CNPV program, the fastest NME approval since 2002. Second oral GLP-1 after the Wegovy pill in December. Two branded oral options at consumer prices accelerates the shift away from compounded GLP-1 injectables.

FDA → Foundayo Approval

Industry

Noom Acquires Tailor Made Compounding

Noom bought Tailor Made Compounding — 503A pharmacy, 46 states, 40,000+ sq ft Kentucky facility, 400+ clinic relationships. Formulary: sermorelin, GHK-Cu, NAD+, oxytocin, HRT. Not a GLP-1 play. A vertical integration bet on preventive care through compliant 503A infrastructure.

MobiHealthNews

Regulatory

FDA Fast-Track Approvals Are Compressing the Compounding Window

FDA's CNPV program: five approvals in 10 months — Foundayo in 50 days, Wegovy HD in 54, a lung cancer drug in 44. Standard review is 10-12 months. Faster branded approvals shrink the supply-gap argument for compounding copies and strengthen the case for differentiated formulations.

FDA → CNPV Program

Research Desk

Peptide Investigational New Drug Pipeline

BPC-157 hamstring trial (Phase 2, 120 participants) and TB-500 cardiovascular trial (Phase 1/2, 80 participants) both actively recruiting.

ReGenTree's Phase 3 RGN-259 trial (thymosin beta 4 ophthalmic solution) hits primary completion this month across 36 sites — potential sterile ophthalmic compounding opportunity if the branded product stalls. Every major compounding peptide is now in a formal IND pathway.

GLP-1 Indications Expanding

UF Phase 2 started April 7 for endometrioid intraepithelial neoplasia.

Weill Cornell Phase 4 tirzepatide in postmenopausal breast cancer survivors.

UTSW semaglutide for subclinical Cushing's.

University of Colorado Phase 2/3 testing semaglutide combined with HRT and antihypertensives for menopausal transition — exactly the multi-drug personalized protocol where 503A pharmacies add unique value.

GLP-1 Delivery Innovation 

Vivani Medical's semaglutide subcutaneous implant enters Phase 1 this month vs. weekly Wegovy.

Shanghai World Leader's semaglutide nasal spray already recruiting Phase 1. New delivery forms could shift prescribing away from injectables entirely.

Low-Dose Naltrexone (LDN) Evidence Base Growing 

UAB dose-finding trial for LDN in ME/CFS (1.5–6.0mg) launches July. University of Arkansas Phase 2 testing LDN for fatigue in prostate cancer patients on ADT. Johns Hopkins Phase 2 evaluating semaglutide + naltrexone for alcohol use disorder — a combo compounders are uniquely positioned to provide.

Intel Briefs

Wegovy HD (7.2mg) Approved March 19 

Higher-dose semaglutide injectable approved in 54 days via CNPV. Novo simultaneously received a Warning Letter on March 5 for systemic adverse-event reporting failures — speed to approval doesn't exempt you from post-market compliance. Pharmaceutical Technology

3.1M Eye Drops Recalled — Sterility Failure 

KC Pharmaceuticals recalled 3.1M bottles (CVS, Walgreens, Publix, Rite Aid) — Class II, lack of sterility assurance. FDA had flagged the same contamination issues in a 2023 warning letter. Sterile manufacturing credibility is a differentiator when big players stumble. US News

Rifampin Manufacturing Ceased 

FDA confirmed capsule production has halted entirely. TB programs are reaching out to 503B facilities for emergency supply. Compounders with capsule capabilities should secure rifampin API now — expect competition and price spikes. FDA Drug Shortages Database

NEW: 503Pharma Formula Library

We just launched a formula library for compounding pharmacies — 90+ ready-to-use formulations, now live in the members area at app.503pharma.com.

Every formula is built for real compounding workflows: USP 795/797-compliant, sterile and non-sterile coverage, beyond-use dating included, and updated as guidance evolves.

What's inside:

• 90+ formulations across sterile and non-sterile categories

• BUD assignments aligned to USP 795/797

• Ready-to-use format — drop into your compounding records directly

• Regularly updated as FDA and USP guidance changes

The members area is free to join. Formula access is a paid feature.

Access the Formula Library

CompoundLearn: Training Built for Compounding Pharmacies

CompoundLearn simplifies USP compliance training so your team can stay inspection-ready without the spreadsheets and paper trails. From onboarding new staff to competency testing, CompoundLearn automates the entire training lifecycle — so you can focus on what matters most: patient safety.

• Full access to 25 training modules and 77 lessons covering critical USP 795, 797, and 800 topics

• Role-based assignments — assign and track the right training curriculum to designated persons/pharmacists-in-charge, compounders, and trainers

• Quizzes and Downloadable certificates that prove that your team knows the material

• 23+ Ready-Made Compliance Templates — Downloadable cleaning logs, sampling records, labeling checklists, and more — ready to use out of the box

• Custom Module Creation — Build pharmacy-specific training for your unique protocols and SOPs

• Team & Role Management — Assign training by role (designated person, compounder, technician) and track progress across your entire organization

[Start Now at CompoundLearn →]

✉️ That’s your 503Pharma weekly digest. Our mission is to keep compounding professionals informed, prepared, and ahead of the curve.